(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) fell by a staggering 30.26% in 21 sessions from €0.19 to €0.13 at 04:13 EST on Wednesday, following the last session’s downward trend. BEL 20 is jumping 1.49% to €3,685.24, after two sequential sessions in a row of gains.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Volatility
BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.27%, a negative 2.81%, and a positive 6.36%.
BIOSENIC’s highest amplitude of average volatility was 11.33% (last week), 5.79% (last month), and 6.36% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for BIOSENIC is 188145 which is 85.32% below its average volume of 301745.
More news about BIOSENIC (BIOS.BR).
